Afatinib
Total Payments
$23.9M
Transactions
244
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $7.3M | 91 | 2 |
| 2017 | $16.6M | 153 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.9M | 244 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| randomized & cetuximab vs afa alone | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.1M | 0 |
| EGFR activ mut HER2 kinase activ mut | Boehringer Ingelheim Pharmaceuticals, Inc. | $1.8M | 0 |
| Adjuvant afatinib for EGFR NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $1.1M | 0 |
| PhI Ib afa & capecitabine solid tumors | Boehringer Ingelheim Pharmaceuticals, Inc. | $1.1M | 0 |
| phII persist. recurr. HER2 & endometrial | Boehringer Ingelheim Pharmaceuticals, Inc. | $822,135 | 0 |
| Na?ve pts with HER2 postive Adv GC USA | Boehringer Ingelheim Pharmaceuticals, Inc. | $564,684 | 0 |
| Afatinib in elderly EGFR M & NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $482,067 | 2 |
| phII afatinib adv penile PSCC | Boehringer Ingelheim Pharmaceuticals, Inc. | $401,215 | 0 |
| phI afatinib rec glioma & brain mets | Boehringer Ingelheim Pharmaceuticals, Inc. | $352,286 | 0 |
| ph I afatinib & MK3475 EGFR & NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $215,286 | 0 |
| stage III treatment EGFRmutation US | Boehringer Ingelheim Pharmaceuticals, Inc. | $205,500 | 0 |
| & necitumumab NSCLC NCCN | Boehringer Ingelheim Pharmaceuticals, Inc. | $185,929 | 0 |
| PhI afatinib postop radiation HNSCC US | Boehringer Ingelheim Pharmaceuticals, Inc. | $137,000 | 0 |
| afatinib & pembrolizumab in squamous NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $134,336 | 0 |
| BIBW 2992 & Vinor. vs Herceptin & Vinor. | Boehringer Ingelheim Pharmaceuticals, Inc. | $57,689 | 0 |
| Afatinib vs. erlotinib in NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $48,474 | 0 |
| Pediatric Phase I basket trial | Boehringer Ingelheim Pharmaceuticals, Inc. | $47,844 | 0 |
| Real World Data on dose adjustment | Boehringer Ingelheim Pharmaceuticals, Inc. | $43,345 | 0 |
| Afatinib advanced refractory UC USA | Boehringer Ingelheim Pharmaceuticals, Inc. | $39,143 | 0 |
| LUX H&N 2, afatinib placebo in L A HNSCC | Boehringer Ingelheim Pharmaceuticals, Inc. | $32,070 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $23.9M
- Total Doctors 2
- Transactions 244
About Afatinib
Afatinib is a drug associated with $23.9M in payments to 2 healthcare providers, recorded across 244 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim Pharmaceuticals, Inc..
Payment data is available from 2017 to 2018. In 2018, $7.3M was paid across 91 transactions to 2 doctors.
The most common payment nature for Afatinib is "Unspecified" ($23.9M, 100.0% of total).
Afatinib is associated with 20 research studies, including "randomized & cetuximab vs afa alone" ($16.1M).